Peptide research is moving beyond the study of molecules that are clearly labelled in the genome.

A growing body of work suggests that larger proteins may contain shorter sequences with independent biological activity. These sequences can remain unnoticed until they are released by proteolytic processing or identified through computational screening.

They are known as encrypted peptides.

The concept has gained renewed attention following the PLOS Biology paper published on 19 August 2026 on encrypted immunity mediated by peptides. The paper focuses on the possibility that immune and antimicrobial functions may be distributed across proteins not traditionally classified as immune molecules. Proteasome-derived defense peptides, or PDDPs, are one example of this emerging research direction.

This is an important frontier. It is not, however, evidence that every peptide fragment is biologically active or suitable for clinical use. The central challenge remains the same: identify a sequence, verify its structure, test its function, and reproduce the result under controlled conditions.

What are encrypted peptides?

An encrypted peptide is a short amino acid sequence embedded within a larger precursor protein.

The larger protein may have a structural, metabolic, or housekeeping role. Its primary biological function may have nothing to do with immunity. However, a smaller sequence within that protein may possess different physicochemical properties once released.

For example, the hidden fragment may:

• Interact with a microbial membrane.
• Bind to a receptor or immune mediator.
• Alter inflammatory signalling.
• Display selective activity against particular organisms.
• Influence cell behaviour independently of the parent protein.

This creates a second layer of biological information. The protein is not only a folded structure with one recognised function. Its sequence may also contain shorter functional regions that become visible after cleavage.

The term “encrypted” is useful because the activity is hidden in plain sight. The sequence is present in the proteome, but it is not annotated as a standalone peptide.

The original research on encrypted peptide antibiotics demonstrated how computational screening could search the human proteome for antimicrobial fragments. The study, published in Nature Biomedical Engineering, showed that short sequences within larger proteins could be prioritised for experimental testing. The work is summarised in the original encrypted peptide study.

How does encrypted immunity work?

The immune system already uses proteolysis to generate biologically important peptides.

Inside cells, the proteasome breaks down proteins into shorter fragments. Some of these fragments are loaded onto major histocompatibility complex class I molecules for antigen presentation. This allows immune cells to inspect intracellular protein production.

The emerging encrypted immunity model asks whether some proteasome-generated fragments may have additional functions.

A proteasome-derived defence peptide could, in principle:

1. Originate within a larger intracellular protein.
2. Be released through proteolytic processing.
3. Persist long enough to interact with another biological system.
4. Contribute to antimicrobial or immunomodulatory activity.

This area requires careful terminology. Not every proteasome product is a defence peptide. Many fragments are rapidly degraded, have no independent activity, or exist only as part of antigen presentation.

PDDP is therefore best understood as a working research descriptor rather than a fully established product class. To classify a fragment as a genuine defence peptide, researchers need evidence of sequence identity, biological activity, mechanism, and reproducibility.

Why computational tools are important

Traditional peptide discovery often begins with a known precursor, a biological observation, or a deliberately designed sequence. Encrypted peptide research reverses this process.

Researchers can begin with a complete proteome and search for short sequences with features associated with a desired activity. Computational tools make this possible at a scale that would be difficult to achieve manually.

A typical discovery workflow may include the following stages.

1. Proteome-wide sequence mining

The system scans protein databases and extracts overlapping sequence windows. A single protein may contain hundreds of potential peptide fragments depending on the length selected.

This creates a large candidate library from proteins that were not previously considered peptide sources.

2. Physicochemical filtering

Candidate sequences can be assessed for characteristics associated with antimicrobial or signalling activity. These may include:

• Net charge.
• Hydrophobicity.
• Amphipathicity.
• Sequence length.
• Predicted solubility.
• Aggregation risk.
• Proteolytic stability.

These features do not prove activity. They help researchers reduce a large search space to a practical number of candidates.

3. Machine-learning prioritisation

Machine-learning models can compare candidate sequences with experimentally characterised peptide datasets. Models may estimate the probability of antimicrobial activity or identify sequence patterns linked to specific biological effects.

The PLOS Biology discussion of digital mining for antibiotic discovery describes this broader approach. It explains how genomics, machine learning, and computational biology can identify candidate peptides at digital speed.

However, model output is a prioritisation tool. It is not a substitute for laboratory validation. Dataset quality, model bias, and the difference between prediction and physiological activity all matter.

4. Structural and mechanistic analysis

Researchers may then use structure-prediction tools, molecular dynamics, or docking approaches to investigate how a peptide could interact with a membrane, receptor, or protein target.

Again, these methods generate hypotheses. They do not establish that the interaction occurs in a biological system.

5. Chemical synthesis and testing

Shortlisted sequences can be synthesised and purified before testing. Experimental assays may assess:

• Antimicrobial activity.
• Selectivity across organisms.
• Cytotoxicity against mammalian cells.
• Membrane disruption.
• Cytokine modulation.
• Stability in relevant biological fluids.
• Activity after proteolytic exposure.

This final stage separates an interesting sequence from a credible research candidate.

How encrypted peptides relate to known research peptides

Encrypted peptide research should not be confused with the marketing practice of describing every peptide as “naturally derived” or “bioactive”.

Several established research peptides illustrate related biological principles, but they are not automatically encrypted peptides.

KPV is a tripeptide fragment derived from alpha-melanocyte-stimulating hormone. It is a clear example of a shorter bioactive fragment originating from a larger precursor. Its biological origin makes it relevant to discussions of peptide processing and fragment activity, although KPV should not be presented as a newly discovered PDDP.

MOTS-c represents a different concept. It is a mitochondrial-derived peptide encoded outside the conventional nuclear genome. This demonstrates that biologically relevant peptide signalling can arise from genomic compartments that were historically given less attention.

BPC-157 is associated with a sequence derived from a gastric protein. It is another useful example of how peptide research can focus on a smaller sequence connected to a larger biological precursor.

GHK-Cu is a naturally occurring copper-binding tripeptide. Its biology highlights how very short sequences can have distinct chemical properties and interact with metal ions or biological pathways.

These examples are useful for understanding peptide origin, processing, and signalling. They do not establish that the compounds have the same mechanism as proteasome-derived defence peptides.

What this means for UK research laboratories

For UK laboratories, the encrypted peptide field creates an opportunity to combine computational biology with established peptide chemistry and assay systems.

A practical research programme should begin with a defined question. For example:

• Does a predicted sequence retain activity after proteolytic processing?
• Does it act through membrane disruption or a receptor-mediated pathway?
• Is activity selective for a target organism?
• Does the fragment alter inflammatory signalling at concentrations that do not cause general cytotoxicity?
• Can the result be reproduced across batches and laboratories?

A protocol-led approach is essential. Researchers should document the source protein, exact sequence, terminal chemistry, purification profile, assay conditions, controls, and statistical analysis.

Material quality is equally important. When comparing computational predictions with experimental results, an impure or misidentified compound can create misleading data. Laboratories evaluating research peptides should request clear batch documentation and use third party tested peptides where appropriate.

At AXIOM Health, our Quality Standards describe a framework based on controlled synthesis, analytical verification, batch-level accountability, and defined release standards. Verification may include HPLC purity profiling and mass spectrometry confirmation of molecular weight.

Our Research Protocols and Research Compendium provide additional context for researchers developing research peptide protocols UK laboratories can adapt to their own approved workflows.

UK teams should also review local requirements for laboratory safety, microbiology work, sample handling, storage, waste disposal, and institutional approval. Research-only materials must remain within their stated intended use. They are not approved medicines and are not intended for human consumption, medical treatment, or diagnosis.

From hidden sequence to validated molecule

Encrypted peptides are reshaping how researchers think about biological discovery.

The next generation of peptide candidates may not come from a dedicated immune gene or a well-known secretory pathway. It may be hidden within a structural protein, a metabolic enzyme, a mitochondrial transcript, or a sequence overlooked during conventional annotation.

Computational tools can help reveal these candidates. They cannot replace experimental discipline.

The strongest research pathway is therefore straightforward:

1. Identify a candidate sequence.
2. Confirm its origin and molecular identity.
3. Prioritise it using transparent computational criteria.
4. Synthesise and characterise the material.
5. Test activity, selectivity, stability, and cytotoxicity.
6. Reproduce the result under controlled conditions.
7. Interpret the findings according to the evidence hierarchy.

That is the difference between a promising sequence and a defensible research result.

For researchers looking to source research peptides UK laboratories can evaluate within a structured framework, AXIOM Health supplies research-grade compounds with defined specifications and analytical verification. Please review the relevant product documentation and research-only position before beginning any work.

Further reading

• Mining biology for antibiotic discovery : PLOS Biology
• Mining for encrypted peptide antibiotics in the human proteome
• Bacterial immune systems as causes and consequences of microbiome structure : PLOS Biology
• AXIOM Health Quality Standards
• The AXIOM Research Compendium

AXIOM Health supplies compounds strictly for in-vitro laboratory research. Products are not approved medicines and are not intended for human consumption, medical treatment, veterinary use, or diagnosis.